dNovo is developing a proprietary direct reprogramming system to generate personalized hair stem cells from patient-derived cells without passing through a pluripotent state. The company has converted human skin cells directly into induced hair stem cells and demonstrated those cells can produce hair in a mouse model. dNovo emerged from stealth and is optimizing its platform to scale the approach and work with potential partners. The team positions direct reprogramming as a quicker, scalable route compared with pluripotent-based methods. dNovo is pre-clinical and says the technology aims to replenish damaged or depleted hair stem cells to address the underlying cause of hair loss. The company was founded in 2018 and is based in San Jose, California.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2022